Penumbra, Inc (PEN) Operating Margin
- Operating margin · 12 months: Value 12.45%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 12.45% | Operating income / revenue. Period ending 2026-06-30. $187.34M ÷ $1.50B × 100 ≈ 12.45% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 187.34M USD | Operating Income (Loss) |
| Revenue | 1.50B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 741.31M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $187.34M | $1.50B | (m) | (m) | $741.31M | 12.45% |
| 2026-03-31 | $187.13M | $1.45B | (m) | (m) | $702.76M | 12.87% |
| 2025-12-31 | $189.25M | $1.40B | (m) | (m) | $663.42M | 13.48% |
| 2025-09-30 | $172.79M | $1.33B | (m) | (m) | $630.26M | 12.95% |
| 2025-06-30 | $159.32M | $1.28B | (m) | (m) | $601.09M | 12.45% |
| 2025-03-31 | $37.53M | $1.24B | (m) | (m) | $583.03M | 3.03% |
| 2024-12-31 | $9.28M | $1.19B | (m) | (m) | $573.99M | 0.78% |
| 2024-09-30 | $1.53M | $1.16B | (m) | (m) | $556.07M | 0.13% |
| 2024-06-30 | $-21.21M | $1.13B | (m) | (m) | $542.26M | -1.87% |
| 2024-03-31 | $77.64M | $1.10B | (m) | (m) | $527.79M | 7.09% |
| 2023-12-31 | $73.55M | $1.06B | (m) | (m) | $506.45M | 6.95% |
| 2023-09-30 | $43.35M | $995.06M | (m) | (m) | $492.06M | 4.36% |
| 2023-06-30 | $36.16M | $937.79M | (m) | (m) | $474.72M | 3.86% |
| 2023-03-31 | $18.14M | $884.64M | (m) | (m) | $461.90M | 2.05% |
| 2022-12-31 | $6.08M | $847.13M | (m) | (m) | $449.72M | 0.72% |
| 2022-09-30 | $-38.81M | $829.93M | (m) | (m) | $447.59M | -4.68% |
| 2022-06-30 | $-35.46M | $806.37M | (m) | (m) | $433.41M | -4.40% |
| 2022-03-31 | $-25.01M | $782.28M | (m) | (m) | $409.43M | -3.20% |
| 2021-12-31 | $-7.50M | $747.59M | (m) | (m) | $378.33M | -1.00% |
| 2021-09-30 | $30.81M | $710.48M | (m) | (m) | $341.43M | 4.34% |
| 2021-06-30 | $1.87M | $671.44M | (m) | (m) | $323.19M | 0.28% |
| 2021-03-31 | $-26.09M | $592.29M | (m) | (m) | $292.41M | -4.40% |
| 2020-12-31 | $-38.94M | $560.41M | (m) | (m) | $287.07M | -6.95% |
| 2020-09-30 | $-26.62M | $538.78M | (m) | (m) | $285.15M | -4.94% |
| 2020-06-30 | $6.52M | $527.20M | (m) | (m) | $278.28M | 1.24% |
| 2020-03-31 | $36.97M | $556.29M | (m) | (m) | $286.10M | 6.65% |
| 2019-12-31 | $47.51M | $547.40M | (m) | (m) | $272.73M | 8.68% |
| 2019-09-30 | $43.60M | $522.93M | (m) | $49.73M | $259.22M | 8.34% |
| 2019-06-30 | $9.77M | $495.24M | (m) | $45.09M | $245.87M | 1.97% |
| 2019-03-31 | $6.25M | $470.68M | (m) | $39.82M | $232.98M | 1.33% |
| 2018-12-31 | $-852.00K | $444.94M | (m) | $36.16M | $226.38M | -0.19% |
| 2018-09-30 | $-3.67M | $420.20M | (m) | (m) | $216.68M | -0.87% |
| 2018-06-30 | $17.87M | $392.30M | (m) | $32.74M | $206.71M | 4.55% |
| 2018-03-31 | $7.26M | $363.25M | (m) | $32.64M | $196.09M | 2.00% |
| 2017-12-31 | $1.17M | $333.76M | (m) | $31.66M | $184.32M | 0.35% |
| 2017-09-30 | $-3.84M | $310.82M | (m) | $29.37M | $174.47M | -1.24% |
| 2017-06-30 | $-5.89M | $294.09M | (m) | $27.74M | $166.24M | -2.00% |
| 2017-03-31 | $-5.23M | $278.61M | (m) | $25.91M | $157.96M | -1.88% |
| 2016-12-31 | $-1.35M | $263.32M | (m) | $23.88M | $148.30M | -0.51% |
| 2016-09-30 | $1.62M | $244.63M | (m) | $23.25M | $135.84M | 0.66% |
| 2016-06-30 | $5.17M | $227.86M | (m) | $21.31M | $124.85M | 2.27% |
| 2016-03-31 | $2.02M | $205.06M | (m) | $19.84M | $115.37M | 0.99% |
| 2015-12-31 | $4.18M | $186.09M | (m) | $18.03M | $101.85M | 2.25% |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $149.13M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $138.30M | (m) | (m) | (m) | (m) |
| 2014-12-31 | $3.01M | $125.51M | (m) | $15.57M | $64.26M | 2.40% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-1.13M | $88.85M | (m) | $14.08M | $44.92M | -1.27% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B |